PAP derived from low risk animal waste (mamma lian/non-mammalian)

PAP derived from high risk animal waste (mammalian/ non-mammalian)

4-aminophenol (PAP)

PAP processed animal protein

Commission Decision of 28 November 1995 on a common technical regulation for attachment requirements for terminal equipment for digital European cordless telecommunications (DECT), public access profile (PAP) applications (95/525/EC) (OJ L 300,13.12.1995, p. 35)

Overall 12 % of the combined study population had an abnormal Pap test suggestive of CIN at Day 1.

Deterioration in oxygenation and elevation in PAP may also occur in neonates with no apparent response to INOmax.

You should continue to follow your doctor’ s advice on cervical smear/ Pap tests and preventative and protective measures.

Among subjects with an abnormal Pap test at Day 1 who were naïve to the relevant vaccine HPV types at Day 1, efficacy of the vaccine remained high.

Among subjects with an abnormal Pap test at Day 1 who were already infected with the relevant vaccine HPV types at Day 1, no vaccine efficacy was observed.

The INOmax dose should not be discontinued abruptly as it may result in an increase in pulmonary artery pressure (PAP) and/ or worsening of blood oxygenation (PaO2).

Results were generally consistent in subgroups according to baseline walking distance, aetiology (primary and CTD-associated PAH), WHO functional class, gender, race, location, mean PAP and PVRI.

seek additional support to complement the contribution of the institutions, which support the established networks, namely, CIHEAM, MAP-PAP/RAC and FAO, and to enhance the work of the four networks;

You should continue to follow your doctor’s advice on cervical smear/Pap test (test to screen for changes in cells of the cervix caused by an HPV infection) and preventative and protective measures.

Among subjects who were naïve to 14 common HPV types and had a negative Pap test at Day 1, administration of Silgard reduced the incidence of CIN 2/ 3 or AIS caused by vaccine- or non-vaccine HPV types by 42.7 % (95 % CI:

Among subjects who were naïve to 14 common HPV types and had a negative Pap test at Day 1, administration of Gardasil reduced the incidence of CIN 2/ 3 or AIS caused by vaccine- or non-vaccine HPV types by 42.7 % (95 % CI:

Commission Decision 95/525/EC of 28 November 1995 on a common technical regulation for attachment requirements for terminal equipment for digital European cordless telecommunication (DECT), public access profile (PAP) applications

In the HPV naïve population (naïve to 14 common HPV types and had a negative Pap test at Day 1), Silgard reduced the proportion of women who experienced, a definitive cervical therapy procedure (Loop Electro-Excision Procedure or Cold-Knife Conization) by 41.9 % (95 % CI:

In the HPV naïve population (naïve to 14 common HPV types and had a negative Pap test at Day 1), Gardasil reduced the proportion of women who experienced, a definitive cervical therapy procedure (Loop Electro-Excision Procedure or Cold-Knife Conization) by 41.9 % (95 % CI:

Whereas Commission Decision 95/525/EC of 28 November 1995 on a common technical regulation for attachment requirements for terminal equipment for digital European cordless telecommunication (DECT), public access profile (PAP) applications (3) is to be incorporated into the Agreement;

Whereas Decision 97/525/EC repeals, with effect from 10 January 1998, Commission Decision 94/525/EC on a common technical regulation for attachment requirements for terminal equipment for digital European cordless telecommunications (DECT), public access profile (PAP) applications, which is incorporated into the Agreement and which is consequently to be repealed under the Agreement,